Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | SOD1 | P00441 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819598 | 0.84 | IDO1 (0.62) | TACR1IDO1HTR2AHTR2BHTR2C | |
| SCHEMBL646907 | 0.82 | IDO1 (0.42) | IDO1SIGMAR1SLC6A4 | |
| SCHEMBL13535480 | 0.82 | TACR1 (0.39) | TACR1IDO1HTR2AHTR2BHTR2C | |
| SCHEMBL348504 | 0.81 | TACR1 (0.54) | TACR1IDO1MRGPRX4BCHEBACE1 | |
| SCHEMBL22022403 | 0.81 | HMGCR (0.49) | TACR1IDO1HMGCR | |
| SCHEMBL350082 | 0.79 | IDO1 (0.46) | TACR1IDO1MRGPRX4BCHEACHE | |
| SCHEMBL10226540 | 0.79 | TP53 (0.39) | IDO1SOD1MAPTLMNAL3MBTL1 | |
| SCHEMBL13252957 | 0.78 | TACR1 (0.45) | TACR1IDO1HTR2AHTR2BHTR2C | |
| SCHEMBL13636300 | 0.78 | HTR2C (0.38) | HTR2AHTR2BHTR2CBCHEBACE1 | |
| SCHEMBL13636301 | 0.78 | HTR2C (0.38) | HTR2AHTR2BHTR2CBCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20080058380-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2008-03-06 | — | — | US | disclosed |
| US-20080058380-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2008-03-06 | — | — | US | disclosed |
| US-7288659-B2 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058380-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PARK7, ACAT1, APP | TACR1 1212/4885IDO1 904/4885HTR2A 1415/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | TACR1 1780/4885IDO1 4177/4885HTR2A 645/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | TACR1 1780/4885IDO1 4177/4885HTR2A 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.